(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best Web-based Courses for Expertise Improvement - 2Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- 3Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- 4Saturn shines with the waxing moon at sunset on Nov. 29
- 5The Best Internet based Courses for Expertise Improvement
- The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- Ergonomic Office Seats for Work spaces
- Wedding trip Objections in the US
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Experience Sports in Dubai: A Daredevil's Aide
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
